Dimethyl fumarate capsules for relapsing multiple sclerosis
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests an oral medication, dimethyl fumarate, which is already used for multiple sclerosis. It aims to see how well it controls relapses in people with relapsing forms of MS. If you have had a relapse in the last year, you might be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of relapsing multiple sclerosis, including CIS, RRMS, or active SPMS, based on 2017 McDonald criteria.
- You must have had at least one relapse in the last 12 months.
- Your MRI must show MS-related changes, or you must have had a recent MRI with gadolinium-enhancing lesions.
- Your disability level must be between 0 and 5 on the EDSS scale (you can still walk without aid).
- You must not have had a relapse in the last 30 days, and your symptoms must be stable.
- You must not have had suicidal thoughts or behaviors recently (within 6 months for thoughts, 5 years for behavior).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
This trial tests a new drug called ublituximab to see if it can reduce flare-ups in children and teens who have relapsing multiple sclerosis. It aims to understand if the treatment is safe and effective for younger patients.
This study tests a new medicine given as a shot under the skin for people with relapsing multiple sclerosis. It aims to see if the medicine is safe and how well it works in reducing MS activity.
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
This study tests two oral medications, diroximel fumarate and dimethyl fumarate, in children and teens with relapsing MS. It aims to see if they are safe and can reduce the number of relapses compared to each other.
This study tests an experimental oral drug, PRO-1562, in two parts: first in healthy volunteers to check safety, then in people with relapsing multiple sclerosis to see if it can reduce disease activity. It may offer a new, convenient treatment option.
Hear when a new Relapsing Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.